EXIMMIUM PTE. LTD.

Eximmium is a pioneering clinical-stage biotech company based in Singapore and Munich, advancing first-in-class cancer immunotherapies that target externalized intracellular neoantigens. Eximmium discovers and develops first-in-class (FIC) antibodies targeting intracellular proteins that are abnormally externalized on the surface of cancer cells—yet absent from normal cell membranes. This novel approach addresses the limitations of conventional immunotherapies, which often target membrane receptors or transport proteins and suffer from off-tumor toxicity and narrow therapeutic windows. By achieving high tumor specificity and broad druggability, Eximmium’s platform supports multiple therapeutic modalities, including TCEs, ADCs, CAR-T, and RIT, with broad applicability across solid tumors. The lead target has been clinically validated through CAR-T therapy for both efficacy and safety, and the corresponding ADC product candidates have demonstrated outstanding preclinical efficacy and safety in models of tumors (e.g. SCLC and PDAC CDX). Backed by comprehensive validation and strong proprietary IP covering the targets, antibodies, and therapeutic applications, Eximmium is well-positioned for development and commercialization partnerships.